January 9, 2025 11:06 AM EST

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Kyle LaHucik

Senior Reporter

Biopharma leaders will descend on San Francisco next week hopeful that the industry’s biggest dealmaking event will finally yield some much sought-after M&A.

The industry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Versant unveils Light Horse with $62M and a partnership with Novartis

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear